CRL vs ICLR vs RVTY
161 measures in 16 categories, one definition each, computed from filings and market data.
CRL27.0
Charles River Laboratories International, Inc.
Healthcare · Medical - Diagnostics & Research
$300.15 −1.95%$14.5B mkt cap
Score DNA
ICLR46.1
ICON Public Limited Company
Healthcare · Medical - Diagnostics & Research
$170.18 −2.83%$13.1B mkt cap
Score DNA
RVTY50.5
Revvity, Inc.
Healthcare · Medical - Diagnostics & Research
$152.64 −1.37%$17.0B mkt cap
Score DNA
Price, rebased to 100 three years ago
CRL ICLR RVTY · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | CRL | ICLR | RVTY |
|---|---|---|---|
| Insider open-market buys, 180d | 1 | 0 | 0 |
| Insider $ bought, 180d | $0.00M | — | — |
| Congress purchases, 180d | 0 | 0 | 4 |
| Last Congress purchase | — | — | 2026-05-04 |
| 13F net change in holders | +14 | +7 | +545 |
| ETFs adding shares, 30d | 547 | 192 | 281 |
| ETFs trimming, 30d | 511 | 99 | 214 |
| Net ETF funds, 30d | +36 | +93 | +67 |
Valuation
16 measures| Measure | CRL | ICLR | RVTY |
|---|---|---|---|
| P/E (TTM) | — | 39.9x
71st
|
71.7x
88th
|
| PEG (P/E ÷ 3-yr EPS CAGR) | — | — | — |
| Price / sales | 3.6x
34th
|
1.6x
3rd
|
5.8x
52nd
|
| Price / book | 5.1x
59th
|
1.4x
11th
|
2.4x
22nd
|
| Price / tangible book | — | — | — |
| Price / free cash flow | 39.0x
74th
|
9.8x
0th
|
30.5x
42nd
|
| Price / operating cash flow | 24.8x
48th
|
8.1x
0th
|
27.1x
52nd
|
| Enterprise value | $17.3B
55th
|
$15.7B
48th
|
$19.4B
59th
|
| EV / sales | 4.3x
38th
|
1.9x
7th
|
6.6x
62nd
|
| EV / EBITDA | 78.4x
86th
|
12.6x
0th
|
25.2x
48th
|
| EV / EBIT | — | 23.4x
24th
|
54.5x
82nd
|
| EV / free cash flow | 46.7x
79th
|
11.7x
0th
|
34.6x
42nd
|
| Earnings yield | -1.6%
31st
|
2.5%
59th
|
1.4%
48th
|
| FCF yield | 2.6%
52nd
|
10.3%
100th
|
3.3%
72nd
|
| Operating cash flow yield | 4.0%
62nd
|
12.3%
100th
|
3.7%
59th
|
| Graham number (per share) | — | $107.67
82nd
|
$55.63
47th
|
Profitability (TTM)
12 measures| Measure | CRL | ICLR | RVTY |
|---|---|---|---|
| Gross margin | 32.2%
28th
|
21.8%
10th
|
52.1%
48th
|
| EBITDA margin | 5.5%
34th
|
15.1%
52nd
|
26.3%
76th
|
| Operating margin | 12.3%
59th
|
10.1%
45th
|
12.3%
55th
|
| EBIT margin | -1.9%
34th
|
8.1%
48th
|
12.2%
59th
|
| Net margin | -6.0%
31st
|
4.0%
45th
|
8.2%
55th
|
| NOPAT margin | 9.8%
52nd
|
8.0%
45th
|
11.3%
62nd
|
| FCF margin | 9.3%
52nd
|
16.3%
66th
|
19.2%
72nd
|
| Operating cash flow margin | 14.6%
48th
|
19.6%
62nd
|
21.6%
69th
|
| R&D / revenue | 0.0%
0th
|
0.0%
0th
|
7.4%
52nd
|
| SG&A / revenue | 18.8%
24th
|
9.4%
7th
|
32.4%
55th
|
| Stock comp / revenue | 1.6%
39th
|
2.1%
54th
|
0.8%
14th
|
| Effective tax rate | 21.0%
52nd
|
21.3%
90th
|
8.0%
14th
|
Returns on capital
11 measures| Measure | CRL | ICLR | RVTY |
|---|---|---|---|
| ROE (on average equity) | -7.7%
22nd
|
3.5%
48th
|
3.2%
44th
|
| ROA | -3.2%
34th
|
2.0%
48th
|
1.9%
45th
|
| ROIC | 6.9%
55th
|
5.5%
48th
|
3.5%
45th
|
| ROCE | -1.2%
34th
|
5.4%
55th
|
3.3%
48th
|
| Return on tangible assets | -1.0%
34th
|
4.1%
52nd
|
2.9%
48th
|
| Cash ROIC (OCF / invested capital) | 10.3%
41st
|
13.6%
59th
|
6.6%
31st
|
| Gross profitability (GP / assets) | 17.1%
38th
|
11.0%
17th
|
12.6%
24th
|
| ROIC, 3-yr average | 3.7%
50th
|
5.6%
67th
|
2.6%
46th
|
| ROIC, 5-yr average | 5.7%
50th
|
5.8%
54th
|
6.0%
58th
|
| ROE, 5-yr average | 6.6%
56th
|
5.5%
52nd
|
6.9%
60th
|
| Incremental ROIC | -163.5%
7th
|
-14.8%
41st
|
-22.7%
37th
|
Growth
17 measures| Measure | CRL | ICLR | RVTY |
|---|---|---|---|
| Revenue growth (TTM YoY) | -0.7%
11th
|
2.0%
14th
|
5.5%
32nd
|
| Revenue growth (QoQ) | 0.8%
7th
|
1.4%
14th
|
2.6%
21st
|
| Revenue CAGR, 3 yr | -1.5%
11th
|
1.5%
22nd
|
-3.6%
4th
|
| Revenue CAGR, 5 yr | 4.1%
44th
|
20.9%
78th
|
-5.1%
7th
|
| Gross profit CAGR, 3 yr | -5.9%
15th
|
-8.1%
7th
|
-6.9%
11th
|
| Operating income CAGR, 3 yr | -8.6%
20th
|
-1.4%
27th
|
-21.5%
7th
|
| Net income growth (TTM YoY) | — | -58.6%
6th
|
-11.9%
19th
|
| Net income CAGR, 3 yr | — | -13.6%
25th
|
-38.0%
0th
|
| EPS growth (TTM YoY) | — | -57.4%
6th
|
-7.4%
19th
|
| EPS CAGR, 3 yr | — | -11.7%
25th
|
-35.4%
8th
|
| EPS CAGR, 5 yr | — | -9.0%
29th
|
-20.0%
7th
|
| FCF growth (TTM YoY) | -35.9%
0th
|
34.2%
83rd
|
14.2%
56th
|
| FCF CAGR, 3 yr | 8.6%
57th
|
52.4%
93rd
|
2.2%
29th
|
| Operating cash flow CAGR, 3 yr | -2.3%
6th
|
44.8%
82nd
|
1.4%
29th
|
| Book value CAGR, 3 yr | -2.5%
28th
|
4.4%
60th
|
0.6%
36th
|
| Dividend CAGR, 3 yr | — | — | 1.9%
0th
|
| Sustainable growth rate | — | 3.5%
12th
|
2.8%
6th
|
Margin history & stability
7 measures| Measure | CRL | ICLR | RVTY |
|---|---|---|---|
| Gross margin, 3-yr average | 33.2%
32nd
|
26.7%
11th
|
52.8%
46th
|
| Operating margin, 3-yr average | 9.7%
54th
|
11.7%
57th
|
13.4%
61st
|
| Net margin, 3-yr average | 1.0%
46th
|
7.5%
61st
|
8.1%
64th
|
| FCF margin, 3-yr average | 11.9%
54th
|
14.3%
64th
|
13.5%
61st
|
| Revenue stability (0-1) | 0.48
18th
|
0.70
36th
|
0.74
43rd
|
| Earnings stability (0-1) | 0.67
79th
|
0.17
25th
|
0.57
64th
|
| Margin stability (0-1) | 0.93
50th
|
0.88
36th
|
0.95
61st
|
Liquidity (latest quarter)
7 measures| Measure | CRL | ICLR | RVTY |
|---|---|---|---|
| Cash & short-term investments | $192.0M
17th
|
$928.4M
72nd
|
$1.0B
76th
|
| Net cash (− = net debt) | −$2.8B
21st
|
−$2.6B
24th
|
−$2.3B
28th
|
| Working capital | $394.4M
48th
|
−$186.0M
7th
|
$1.0B
66th
|
| Current ratio | 1.35
17th
|
0.95
7th
|
1.80
41st
|
| Quick ratio | 1.04
17th
|
0.95
14th
|
1.50
41st
|
| Cash ratio (cash + ST investments / current liabilities) | 0.17
10th
|
0.24
17th
|
0.80
45th
|
| Defensive interval (days) | 415 days
41st
|
1,374 days
93rd
|
546 days
62nd
|
Leverage & solvency (latest quarter)
13 measures| Measure | CRL | ICLR | RVTY |
|---|---|---|---|
| Total debt | $3.0B
69th
|
$3.5B
76th
|
$3.3B
72nd
|
| Debt / equity | 1.07
89th
|
0.37
41st
|
0.46
44th
|
| Net debt / equity | 1.00
89th
|
0.27
44th
|
0.32
59th
|
| Debt / assets | 40.2%
83rd
|
21.3%
34th
|
27.7%
41st
|
| Debt / capital | 51.6%
86th
|
27.1%
39th
|
31.6%
43rd
|
| Debt / EBITDA | 13.73
95th
|
2.81
38th
|
4.36
71st
|
| Net debt / EBITDA | 12.86
95th
|
2.06
48th
|
3.02
57th
|
| Interest coverage (EBIT / interest) | −0.7x
36th
|
3.6x
56th
|
3.8x
60th
|
| Cash interest coverage | 5.5x
40th
|
8.7x
64th
|
6.7x
48th
|
| Debt payback (years of OCF) | 5.2 yrs
70th
|
2.2 yrs
26th
|
5.3 yrs
74th
|
| Liabilities / assets | 62.2%
79th
|
42.8%
41st
|
40.0%
34th
|
| IS credit model rating | BB- | BBB+ | A- |
| Implied credit spread (bps) | 550
79th
|
225
55th
|
175
45th
|
Efficiency
11 measures| Measure | CRL | ICLR | RVTY |
|---|---|---|---|
| Asset turnover | 0.53
45th
|
0.50
41st
|
0.24
3rd
|
| Fixed asset turnover | 2.19
14th
|
16.50
97th
|
4.80
62nd
|
| Inventory turnover | 8.7
68th
|
— | 3.6
20th
|
| Receivables turnover | 6.3
41st
|
3.2
0th
|
4.2
10th
|
| Days sales outstanding | 58 days
59th
|
113 days
100th
|
86 days
90th
|
| Days inventory outstanding | 42 days
32nd
|
— | 100 days
80th
|
| Days payables outstanding | 19 days
14th
|
6 days
0th
|
45 days
52nd
|
| Cash conversion cycle (days) | 81 days
62nd
|
107 days
72nd
|
141 days
90th
|
| Capex / revenue | 5.3%
72nd
|
3.3%
45th
|
2.4%
28th
|
| Capex / depreciation | 0.71
55th
|
0.48
28th
|
0.17
7th
|
| Operating expense ratio | 24.2%
28th
|
9.4%
7th
|
44.9%
48th
|
Cash flow & earnings quality
7 measures| Measure | CRL | ICLR | RVTY |
|---|---|---|---|
| Operating cash flow / net income | — | 4.93
100th
|
2.65
88th
|
| FCF / net income | — | 4.09
100th
|
2.35
88th
|
| FCF / operating cash flow | 63.7%
26th
|
83.0%
61st
|
88.9%
74th
|
| Capex / operating cash flow | 36.3%
74th
|
17.0%
39th
|
11.1%
26th
|
| Accruals ratio | -10.9%
21st
|
-7.8%
28th
|
-3.2%
69th
|
| Sloan accruals ratio | -3.9%
28th
|
-9.2%
3rd
|
-7.8%
14th
|
| Earnings quality score (0-1) | — | 0.75
0th
|
1.00
24th
|
Scores & forensic checks
15 measures| Measure | CRL | ICLR | RVTY |
|---|---|---|---|
| IS score | 27
7th
|
46
38th
|
50
52nd
|
| IS profitability | 18
24th
|
19
28th
|
35
48th
|
| IS growth | 32
11th
|
22
0th
|
34
14th
|
| IS value | 28
3rd
|
45
66th
|
40
48th
|
| IS momentum | 35
4th
|
56
21st
|
66
39th
|
| IS risk (safety) | 50
21st
|
50
21st
|
65
34th
|
| IS quality | 41
14th
|
66
59th
|
70
62nd
|
| IS balance sheet | 31
24th
|
53
59th
|
55
62nd
|
| IS earnings quality | 43
14th
|
59
38th
|
69
52nd
|
| IS cash flow | 30
38th
|
74
86th
|
69
72nd
|
| Piotroski F-score (0-9) | 4
7th
|
6
41st
|
6
41st
|
| Altman Z-score | 2.2
31st
|
2.0
28th
|
2.7
34th
|
| Beneish M-score | −3.11
7th
|
−2.63
43rd
|
−2.62
46th
|
| Ohlson O-score | −6.42
72nd
|
−8.47
41st
|
−8.69
34th
|
| IS credit score | 35
17th
|
61
38th
|
65
48th
|
Size (TTM)
8 measures| Measure | CRL | ICLR | RVTY |
|---|---|---|---|
| Market cap | $14.5B
52nd
|
$13.1B
48th
|
$17.0B
55th
|
| Revenue | $4.0B
62nd
|
$8.3B
83rd
|
$2.9B
59th
|
| EBITDA | $220.5M
45th
|
$1.2B
69th
|
$767.0M
59th
|
| Net income | −$238.5M
7th
|
$328.9M
62nd
|
$237.6M
59th
|
| Free cash flow | $370.6M
52nd
|
$1.3B
86th
|
$559.3M
62nd
|
| Total assets | $7.5B
69th
|
$16.4B
79th
|
$12.0B
72nd
|
| Shareholders' equity | $2.8B
66th
|
$9.4B
90th
|
$7.2B
76th
|
| Employees | 19,000
79th
|
40,200
83rd
|
11,000
66th
|
Price performance
9 measures| Measure | CRL | ICLR | RVTY |
|---|---|---|---|
| 1 day | −1.9% | −2.8% | −1.4% |
| 1 week | −0.5% | +3.7% | −1.0% |
| 1 month | +6.6% | +0.3% | +4.0% |
| 3 months | +36.7% | +2.4% | +43.4% |
| 6 months | +63.3% | +42.2% | +62.4% |
| Year to date | +48.3% | −9.8% | +55.6% |
| 1 year | +75.9% | −9.4% | +65.8% |
| 3 years, cumulative | +52.4% | −31.7% | +40.9% |
| 5 years, cumulative | −26.6% | −35.8% | −9.3% |
Technicals
4 measures| Measure | CRL | ICLR | RVTY |
|---|---|---|---|
| RSI 14 | 55.7 | 53.2 | 59.2 |
| From 52-week high | −9.9% | −16.5% | −8.2% |
| From 52-week low | +105.4% | +155.6% | +87.9% |
| Beta | 1.40 | 1.24 | 1.06 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17